Cargando…

Mucin 20 modulates proteasome capacity through c‐Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma

Mantle cell lymphoma (MCL) is a haematologic malignancy. The proteasome inhibitor (PI) bortezomib has been approved to treat MCL, but resistance has emerged through mechanisms that remain unclear. This study aimed to explore the mechanism of PI resistance in MCL and identify new targets for this pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaobin, Shirazi, Fazal, Yan, Wei, Liu, Xiaoyu, Wang, Hua, Orlowski, Robert Z., Wang, Huihan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572801/ https://www.ncbi.nlm.nih.gov/pubmed/34651428 http://dx.doi.org/10.1111/jcmm.16953

Ejemplares similares

Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug
por: Tundo, Grazia Raffaella, et al.
Publicado: (2022)

Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
por: Guan, Shan, et al.
Publicado: (2016)

The 20S Proteasome Splicing Activity Discovered by SpliceMet
por: Liepe, Juliane, et al.
Publicado: (2010)

Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
por: Efentakis, Panagiotis, et al.
Publicado: (2020)

Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors
por: Jones, Richard J., et al.
Publicado: (2020)

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity
por: Chen-Scarabelli, Carol, et al.
Publicado: (2017)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells
por: Shi, Yonghua, et al.
Publicado: (2016)

H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
por: Lee, Min Jae, et al.
Publicado: (2019)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models
por: Crawford, L J, et al.
Publicado: (2014)

Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma
por: Axelrod, M, et al.
Publicado: (2014)

A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress
por: Ben Younes, Khaoula, et al.
Publicado: (2017)

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis
por: Li, Shi-Jun, et al.
Publicado: (2020)

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
por: Lee, Susan J., et al.
Publicado: (2016)

Combination regimen of granulocyte colony-stimulating factor and recombinant human thrombopoietin improves the curative effect on elderly patients with leukemia through inducing pyroptosis and ferroptosis of leukemia cells
por: Wang, Xiaobin, et al.
Publicado: (2022)

Smoldering mantle cell lymphoma
por: Ye, Haige, et al.
Publicado: (2017)

Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice
por: Park, Ji Eun, et al.
Publicado: (2017)

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma
por: Gao, Minjie, et al.
Publicado: (2016)

The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5
por: Han, Bo, et al.
Publicado: (2015)

Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line
por: Hosseini, Maryam Sadat, et al.
Publicado: (2019)

Educational Case: Mantle Cell Lymphoma
por: Mai, Brenda, et al.
Publicado: (2020)

p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma
por: Chen, Yingtong, et al.
Publicado: (2023)

Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma
por: Wang, Hongyu, et al.
Publicado: (2023)

Racial differences in mantle cell lymphoma in the United States
por: Wang, Yu, et al.
Publicado: (2014)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
por: Shen, Xuxing, et al.
Publicado: (2021)

FNC efficiently inhibits mantle cell lymphoma growth
por: Zhang, Yan, et al.
Publicado: (2017)

Current trials for frontline therapy of mantle cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2018)

A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2021)

Mantle cell lymphoma with features of marginal-zone lymphoma
por: Randen, Ulla, et al.
Publicado: (2011)

Primary gastric mantle cell lymphoma
por: Petranovic, Duska, et al.
Publicado: (2012)

Mantle cell lymphoma with skin involvement
por: Kalińska-Bienias, Agnieszka, et al.
Publicado: (2015)

Esophageal location of mantle cell lymphoma
por: Michopoulos, Spyros
Publicado: (2016)

Tracheobronchial involvement of mantle cell lymphoma
por: Tong, Lin, et al.
Publicado: (2018)

Mantle Cell Lymphoma Case Report
por: Podzolkov, V.I., et al.
Publicado: (2018)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Tackling Mantle Cell Lymphoma in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells
por: Li, Qian, et al.
Publicado: (2018)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l5m2gi3bm496qsntrghvrbuq2o